ATE210643T1 - Prostaglandin-analoga zur behandlung von osteoporose - Google Patents
Prostaglandin-analoga zur behandlung von osteoporoseInfo
- Publication number
- ATE210643T1 ATE210643T1 AT93921469T AT93921469T ATE210643T1 AT E210643 T1 ATE210643 T1 AT E210643T1 AT 93921469 T AT93921469 T AT 93921469T AT 93921469 T AT93921469 T AT 93921469T AT E210643 T1 ATE210643 T1 AT E210643T1
- Authority
- AT
- Austria
- Prior art keywords
- osteoporosis
- treatment
- prostaglandins
- compounds
- prostaglandin analogues
- Prior art date
Links
- 208000001132 Osteoporosis Diseases 0.000 title abstract 2
- 229940006138 antiglaucoma drug and miotics prostaglandin analogues Drugs 0.000 title 1
- 229940122361 Bisphosphonate Drugs 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 abstract 2
- 150000003180 prostaglandins Chemical class 0.000 abstract 2
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 150000004663 bisphosphonates Chemical class 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 229940124447 delivery agent Drugs 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000011164 ossification Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/5537—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom the heteroring containing the structure -C(=O)-N-C(=O)- (both carbon atoms belong to the heteroring)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
- C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
- C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/944,149 US5409911A (en) | 1992-09-11 | 1992-09-11 | Prostaglandin analog for treating osteoporosis |
PCT/US1993/008529 WO1994006750A1 (en) | 1992-09-11 | 1993-09-09 | Prostaglandin analog for treating osteoporosis |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE210643T1 true ATE210643T1 (de) | 2001-12-15 |
Family
ID=25480889
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT93921469T ATE210643T1 (de) | 1992-09-11 | 1993-09-09 | Prostaglandin-analoga zur behandlung von osteoporose |
Country Status (9)
Country | Link |
---|---|
US (1) | US5409911A (de) |
EP (1) | EP0662075B1 (de) |
JP (1) | JPH08501546A (de) |
AT (1) | ATE210643T1 (de) |
AU (1) | AU677597B2 (de) |
CA (1) | CA2144093A1 (de) |
DE (1) | DE69331326T2 (de) |
ES (1) | ES2169046T3 (de) |
WO (1) | WO1994006750A1 (de) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5914099A (en) * | 1995-05-12 | 1999-06-22 | Merck & Co., Inc. | Prevention of tooth loss by the administration of alendronate or its salts |
WO1996039107A1 (en) * | 1995-06-06 | 1996-12-12 | Merck & Co., Inc. | Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices |
JPH11506757A (ja) * | 1995-06-06 | 1999-06-15 | メルク エンド カンパニー インコーポレーテッド | 二ナトリウムアレンドロネート製剤 |
US6303155B1 (en) | 1996-02-15 | 2001-10-16 | Hadasit Medical Research Services And Development Company, Ltd. | Treatment of conditions associated with impairment in the level of the parathyroid hormone |
US5935607A (en) * | 1996-02-15 | 1999-08-10 | Hadasit Medical Research Services And Development Company Ltd. | Treatment of osteoporosis |
IL120270A0 (en) * | 1996-02-28 | 1997-06-10 | Pfizer | Combination therapy to treat osteoporosis |
HN1996000101A (es) * | 1996-02-28 | 1997-06-26 | Inc Pfizer | Terapia combinada para la osteoporosis |
AU4881697A (en) | 1996-12-20 | 1998-07-17 | Pfizer Inc. | Prevention and treatment of skeletal disorder with EP2 receptor subtype se lective prostaglandin E2 agonists |
AU731153B2 (en) * | 1997-09-09 | 2001-03-22 | Duke University | Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists |
IL134760A0 (en) * | 1997-09-09 | 2001-04-30 | Procter & Gamble | Method of increasing bone volume using non-naturally-occurring fp selective agonists |
ID24845A (id) * | 1997-09-09 | 2000-08-24 | Procter & Gamble | Prostaglandin tetrahidro tersubstitusi c16-c20 aromatik yang berguna sebagai agonis fp |
CA2338000C (en) * | 1998-07-17 | 2009-12-15 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Water-soluble 4-thio-maleimido derivatives and methods for their production |
US6747055B1 (en) | 1998-07-17 | 2004-06-08 | The United States Of America As Represented By The Department Of Health And Human Services | Water-soluble drugs and methods for their production |
US6331533B1 (en) | 1998-11-16 | 2001-12-18 | Merck & Co., Inc. | Method for inhibiting dental resorptive lesions |
US6121253A (en) * | 1998-11-20 | 2000-09-19 | Merck Frosst Canada & Co. | Prostaglandin conjugates for treating or preventing bone disease |
AU3385900A (en) * | 1999-03-05 | 2000-09-21 | Procter & Gamble Company, The | Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives |
WO2000051980A1 (en) | 1999-03-05 | 2000-09-08 | The Procter & Gamble Company | C16 unsaturated fp-selective prostaglandins analogs |
EP1158987A1 (de) * | 1999-03-05 | 2001-12-05 | The Procter & Gamble Company | Verfahren zur erhohung des knochenvolumens mittels nicht natürlich vorkommenden fp agonisten und antiresorptiva |
MXPA01011227A (es) | 1999-05-04 | 2002-07-02 | Strakan Ltd | Glicosidas androgenas y su actividad androgenica. |
CA2308532C (en) * | 1999-05-12 | 2005-11-29 | Gador S.A. | Use of bisphosphonates for the treatment of osteogenesis imperfecta |
DE60003435T2 (de) * | 1999-08-04 | 2004-05-19 | The Procter & Gamble Company, Cincinnati | Neue 2-decarboxy-2-phosphinico prostaglandin f analoge |
EP1267888A4 (de) | 2000-01-04 | 2005-12-28 | Univ California | Verwendung von niedrigdosierten bisphosphonaten zur verhinderung der verkalkung von herz und arterien |
WO2001051497A1 (en) * | 2000-01-14 | 2001-07-19 | Strakan Limited | Novel bisphosphonates and uses thereof |
US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US20020146439A1 (en) * | 2000-03-31 | 2002-10-10 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins |
US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
US20020037914A1 (en) * | 2000-03-31 | 2002-03-28 | Delong Mitchell Anthony | Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins |
CN100463910C (zh) * | 2006-12-14 | 2009-02-25 | 西北工业大学 | 二膦酸盐衍生物的制备方法 |
WO2008134828A2 (en) | 2007-05-04 | 2008-11-13 | Katholieke Universiteit Leuven | Tissue degeneration protection |
US8623918B2 (en) * | 2008-10-29 | 2014-01-07 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
US8722739B2 (en) * | 2008-10-29 | 2014-05-13 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
CA2738045C (en) * | 2010-05-28 | 2019-02-19 | Simon Fraser University | Conjugate compounds, methods of making same, and uses thereof |
WO2012113571A1 (en) | 2011-02-24 | 2012-08-30 | Ktb Tumorforschungsgesellschaft Mbh | Bisphosphonate-prodrugs |
CN106316910A (zh) | 2011-06-02 | 2017-01-11 | 奇诺因私人有限公司 | 用于制备前列腺素酰胺的新的方法 |
US9650414B1 (en) | 2014-05-30 | 2017-05-16 | Simon Fraser University | Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof |
EP3307747A4 (de) | 2015-06-12 | 2019-02-27 | Simon Fraser University | Amid-verlinkte ep4-agonist-bisphosphonatverbindungen und verwendungen davon |
WO2017152044A1 (en) | 2016-03-04 | 2017-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for muscle regeneration using prostaglandin e2 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3975404A (en) * | 1971-05-04 | 1976-08-17 | The Upjohn Company | Bicyclic lactone intermediates |
US3927197A (en) * | 1974-04-19 | 1975-12-16 | Pfizer | Tertiary alcohol stabilized E-series prostaglandins |
US4018892A (en) * | 1975-08-06 | 1977-04-19 | Pfizer Inc. | Bone deposition by 16-aryl-13,14-dihydro-PGE2 p-biphenyl esters |
US4097601A (en) * | 1977-08-26 | 1978-06-27 | Pfizer Inc. | Bone deposition by 2-descarboxy-2-(tetrazol-5-yl)-11-dexosy-16-aryl prostaglandins |
US4171331A (en) * | 1978-06-05 | 1979-10-16 | Miles Laboratories, Inc. | 1 And 2-substituted analogues of certain prostaglandins |
US4621100A (en) * | 1981-09-25 | 1986-11-04 | The Upjohn Company | Treatment of osteoporosis with prostaglandins |
ATE66608T1 (de) * | 1984-04-30 | 1991-09-15 | Procter & Gamble | Ausruestung fuer die behandlung der osteoporose. |
JPS6191137A (ja) * | 1984-10-11 | 1986-05-09 | Kao Corp | 外用薬剤組成物 |
DE3519361A1 (de) * | 1985-05-30 | 1986-12-04 | Boehringer Ingelheim International GmbH, 6507 Ingelheim | (gamma)-ifn als wirkstoff zur hemmung (verhinderung) von abbauprozessen im knochen |
US4761406A (en) * | 1985-06-06 | 1988-08-02 | The Procter & Gamble Company | Regimen for treating osteoporosis |
EP0341961A3 (de) * | 1988-05-09 | 1990-06-20 | Merck & Co. Inc. | Polymalonsäuren als Knochenaffinitätsagent |
JPH0778024B2 (ja) * | 1988-10-14 | 1995-08-23 | 藤沢薬品工業株式会社 | 医薬化合物とジホスホン酸誘導体の結合体を含有する医薬用製剤 |
JPH0759505B2 (ja) * | 1988-11-17 | 1995-06-28 | 帝人株式会社 | シクロペンテノン類を活性成分とする骨形成促進剤 |
US5071655A (en) * | 1990-01-12 | 1991-12-10 | Baylink David J | Pharmaceutical combination for treatment of bone-wasting diseases |
EP0496520A1 (de) * | 1991-01-22 | 1992-07-29 | Merck & Co. Inc. | Knochenaktive Verbindungen |
US5118667A (en) * | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
-
1992
- 1992-09-11 US US07/944,149 patent/US5409911A/en not_active Expired - Lifetime
-
1993
- 1993-09-09 DE DE69331326T patent/DE69331326T2/de not_active Expired - Fee Related
- 1993-09-09 AT AT93921469T patent/ATE210643T1/de not_active IP Right Cessation
- 1993-09-09 JP JP6508175A patent/JPH08501546A/ja not_active Ceased
- 1993-09-09 EP EP93921469A patent/EP0662075B1/de not_active Expired - Lifetime
- 1993-09-09 WO PCT/US1993/008529 patent/WO1994006750A1/en active IP Right Grant
- 1993-09-09 CA CA002144093A patent/CA2144093A1/en not_active Abandoned
- 1993-09-09 ES ES93921469T patent/ES2169046T3/es not_active Expired - Lifetime
- 1993-09-09 AU AU48554/93A patent/AU677597B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
EP0662075B1 (de) | 2001-12-12 |
ES2169046T3 (es) | 2002-07-01 |
DE69331326T2 (de) | 2002-11-07 |
EP0662075A4 (de) | 1998-05-20 |
CA2144093A1 (en) | 1994-03-31 |
WO1994006750A1 (en) | 1994-03-31 |
JPH08501546A (ja) | 1996-02-20 |
AU677597B2 (en) | 1997-05-01 |
US5409911A (en) | 1995-04-25 |
AU4855493A (en) | 1994-04-12 |
DE69331326D1 (de) | 2002-01-24 |
EP0662075A1 (de) | 1995-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE210643T1 (de) | Prostaglandin-analoga zur behandlung von osteoporose | |
IL104109A (en) | Pharmaceutical compositions containing aldenorate for treating periodontal diseases | |
EA200000682A1 (ru) | Новые ацилгуанидиновые производные в качестве ингибиторов резорбции костной ткани и антагонистов витронектиновых рецепторов | |
ATE232874T1 (de) | Prostaglandin-konjugate zur behandlung von knochenkrankheiten | |
DE60211935D1 (de) | Alkandiol derivate zur behandlung von knochenkrankheiten | |
WO2001081312A3 (en) | Method of treatment using phenyl and biaryl derivatives as prostaglandin e inhibitors and compounds useful therefore | |
EA200500088A1 (ru) | Трициклические модуляторы ядерного рецептора стероидного гормона | |
GR3033127T3 (en) | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 | |
ATE417615T1 (de) | Pharmazeutische zusammenstellungen und zubereitungen zur behandlung von stoffwechselbedingten knochenerkrankungen | |
EE9600191A (et) | Püridüülbisfosfonaatide kasutamine terapeutiliste toimeainetena | |
SE8903529D0 (sv) | Medical use | |
DE60212621D1 (de) | Verabreichung von bisphosphonaten durch inhalation zur behandlung von knochenresorption und osteoporosis | |
KR970705400A (ko) | 골 활성 포스포네이트 및 부갑상선 호르몬을 사용한 골다공증의 치료방법(methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone) | |
DE69206607D1 (de) | Behandlung von kognitiven störungen. | |
DE50108711D1 (de) | Verwendung von substituierten 6-dimethylaminomethyl-1-phenyl-cyclohexanverbindungen zur therapie der harninkontinenz | |
ATE172118T1 (de) | Verwendung von östriol zur herstellung einen transdermalen therapeutischen systeme zur behandlung von klimakterischer osteoporose | |
DE60108775T8 (de) | Methode zur behandlung von schlaganfall | |
MX9606180A (es) | Piridilbisfosfonatos para utilizarse como un agente terapeutico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |